The demand for oxycodone treatment in international healthcare markets is growing rapidly, with Cambodia emerging as an important destination for quality opioid analgesics in Southeast Asia. As effective pain management and advanced cancer care become national priorities, healthcare systems in the region require licensed pharmaceutical partners capable of supplying stringent, high-grade oxycodone products in both immediate and extended-release forms.

Vonage Pharma proudly supports this need by producing a full portfolio, including Oxycodone Immediate-Release (IR) 5 mg, Oxycodone 15 mg IR, Oxycodone 30 mg (Faroxy) IR, Oxycodone Extended-Release (ER) 10 mg, ER 20 mg, and ER 40 mg tablets. This comprehensive offering ensures Cambodian providers have reliable access to formulations that address specific patient requirements and enable best-in-class pain relief practices.

Global and Regional Oxycodone Market Trends

The worldwide oxycodone market is currently valued at over USD 7 billion (2025), with forecasts pointing to strong growth—an estimated CAGR of 5.61% through 2034. Asia-Pacific, including Cambodia, ranks as the fastest-expanding region. Several factors drive this trend: an aging population, rising rates of chronic pain and cancer, and improved healthcare infrastructure continuing to adapt Western pain management models. (precedenceresearch)

Prescription oxycodone is primarily used to treat moderate to severe pain, especially when non-opioid options prove insufficient. Its introduction from Western medical protocols to Asia-Pacific markets like Cambodia was catalyzed by efforts to improve cancer support, offer reliable surgical recovery, and meet rising standards for pain management. (precedenceresearch)

Pharmaceutical Trends in Cambodia

Cambodia’s pharmaceutical industry is experiencing a pivotal transformation. According to market analysts, the Cambodia Oxycodone Drugs Market is projected to grow from 2025 to 2031 due to several factors:

• Healthcare spending in Cambodia is increasing, enabling more hospitals and clinics to offer regulated opioid prescriptions. (6wresearch)

• Both public hospitals and retail pharmacies are now significant distribution channels for advanced pain treatment, including oxycodone in both IR and ER dosage forms. (6wresearch)

• Social shifts, such as increased awareness of palliative care and chronic pain disorders, are boosting the demand for licensed, internationally sourced oxycodone treatment—particularly for oncology, trauma, and hospice applications.

Cambodia is also investing in regulatory modernization. The government and Ministry of Health are expanding the number of “voluntary community-based drug treatment sites,” aimed at both supporting recovery expectations and reducing misuse through better clinical oversight. (amnesty)

Meeting the Need: Oxycodone Dosage Forms

Vonage Pharma has developed a versatile portfolio to accommodate Cambodia’s diverse healthcare requirements:

• Oxycodone Immediate-Release (IR) 5 mg
  Low-dose, fast-acting for initial and breakthrough pain relief.

• Oxycodone Extended-Release (ER) 10 mg
  Steady release over 12 hours for chronic pain.

• Oxycodone Immediate-Release (IR) 15 mg
  Medium dose for acute pain and dose escalation.

• Oxycodone Extended-Release (ER) 20 mg
  Higher dose for persistent moderate to severe pain.

• Oxycodone 30 mg (Faroxy) Immediate-Release (IR)
  High-strength IR for severe pain with rapid onset.

• Oxycodone Extended-Release (ER) 40 mg
  Maximum strength for long-lasting severe pain relief.

Together, these formulations support clinicians in offering evidence-based, safe, and flexible pain management regimens in compliance with global standards.

Oxycodone Treatment: Market Statistics

• By 2031, Cambodia’s oxycodone drug market is forecast to see substantial expansion, supported by increased import and export activities, particularly with established pharmaceutical partners. (6wresearch)

• Global demand is projected to reach over USD 11.5 billion by 2034, as opioid therapies become a cornerstone for pain care among both aging and post-surgical patient groups. (precedenceresearch)

• Data indicate that Asia-Pacific, now adapting to Western guidelines, is rapidly reducing the treatment gap for moderate to severe chronic pain. (precedenceresearch)

• Immediate-release oxycodone remains favored during initial, short-duration or breakthrough pain management, while extended-release forms play an increasing role for continuous, stable pain control—especially in cancer and palliative contexts.

The Regulatory and Public Health Dimension

Cambodia’s journey toward modern oxycodone treatment must address certain public health and regulatory challenges, such as:

• Ensuring equitable access to pain relief while maintaining controls against diversion and misuse.

• Training healthcare professionals in the responsible use of opioids to minimize risks yet maximize therapeutic value.

• Aligning imports and exports of finished dosage forms with evolving legal frameworks and pharmaceutical quality standards. (amnesty)

Recent government actions signal a shift to a more health-centered response, supporting the establishment of community-based programs and reinforcing the responsible use of all opioid analgesics, including oxycodone. (amnesty)

Vonage Pharma’s Role in Cambodia’s Oxycodone Supply Chain

Through consistent investment in R&D, GMP-certified operations, and global logistics, Vonage Pharma delivers high-grade oxycodone tablets. These products are regulatorily compliant and supplied to the Cambodian market. By covering every major dosage, the company enables hospital pharmacists, pain specialists, oncologists, and hospice experts to tailor therapy precisely.

The company’s oxycodone treatment lineup ranges from low-dose IR to potent ER strengths. It is designed to align with Cambodia’s policies. These policies focus on safe opioid supply, healthcare improvement, and investment in pain specialty care.

Conclusion

In summary, the future of oxycodone treatment in Cambodia is defined by increased demand. Access to treatment is improving. The regulatory landscape is also evolving. Vonage Pharma stands ready to help lead this transformation. We supply a robust array of oxycodone IR and ER formulations. We engineer our products for quality, safety, and therapeutic precision.

Healthcare providers, clinics, and medical procurement agencies can count on Vonage Pharma as a reliable export partner. We offer advanced oxycodone dosage forms to strengthen Cambodia’s pain management. Our products help improve patient quality of life.